bioecon Member area
Suppliers · Producer · Industrial biotech & bio-based materials

Amano Enzyme

We’re Amano Enzyme (or Amano for short), and our dedication to advancing enzyme technology has been unwavering for generations. Originally founded in 1899, we’re now proud to be the global leader in specialty enzymes and the largest manufacturer in Japan. Not only that, but we focus on both classical (non-GMO) and modern biotechnology as part of our commitment to a happier, healthier world. …

active JapanAsia Founded 1899 checked 2026-10-05

Profile

Amano Enzyme Inc. is a Japan-based specialty enzyme manufacturer and seller, making enzyme agents for pharmaceutical, food, and manufacturing industries plus diagnostic reagents, and also producing pharmaceuticals, veterinary medicines, and feed additives. Core technology centers on microbial enzyme discovery and production using strain screening (20,000+ strain library), classical mutagenesis/GMO/protein engineering, and fermentation/koji processes (including koji and liquid fermentation), plus extraction/purification and fermentation controls. Founded in 1899 (began enzyme manufacturing in 1948) and established 26 Aug 1948 for Amano Enzyme Inc.. Headquarters: Nagoya City, Aichi, Japan (2-7-1 Nishiki, Naka-ku, 460-8630). It is privately held (no stock listing shown in provided sources); ownership investors/funding: not disclosed in the provided results. Scale: 390 million yen capital and 480 employees. Key facilities include three Japanese plants (Nagoya plant, Yoro plant, Shiga plant) and an Innovation Center in Gifu. Latest 2025–2026 developments from provided materials: Sustainability Report 2025 covers FY2022–FY2025 highlights (biogas recovery growth and a Yoro sludge-to-fertilizer initiative; plus factory automation/AI/IoT for quality control). Corporate deck is dated June 2026, indicating the company is active as of then. Recent patent activity includes several applications with first filing dates in 2025–2026 (e.g., 2025 enzyme-related WO applications; 2026 US application on modified transglutaminase). Key partners/customers: not specified in the provided results.

Sources#

Industry
Alternative proteins, Cosmetics, Energy, Feed, Food ingredients, Industrial chemistry, Veterinary, Water
Topics
Enzymes & biocatalysis, Hyaluronic acid, collagen & cosmetic bio-actives, Yeast, fermentation & food ingredients, Plant-based meat, dairy & egg
Role
Producer — “…apan-based specialty enzyme manufacturer and seller, making enzyme agents for pharmaceutical, food, and manufa…”

Bio-solutions it supplies 0

Not yet cited as a supplier in a graded solution.

Verified product links: Edoxaban → I02; Dextranase → I02;

What they offer

Sites 9

  • Tokyo Office (Tokyo, Japan)
  • Innovation Center (Kakamigahara City, Gifu, Japan)
  • Nagoya Plant (Kitanagoya City, Aichi, Japan)
  • Yoro Plant (Ogaki City, Gifu, Japan)
  • Shiga Plant (Konan City, Shiga, Japan)
  • Amano Enzyme U.S.A. Co., Ltd. (USA)
  • Amano Enzyme Europe Ltd. (UK)
  • Amano Enzyme Manufacturing (China), Ltd. (China)
  • Amano Enzyme Asia Pacific Co., Ltd. (Thailand)

Production, R&D and other sites from the company's website and automated research; street addresses omitted.

Subsidiaries: Amano Enzyme U.S.A. Co., Ltd. · Amano Enzyme Europe Ltd. · Amano Enzyme Manufacturing (China), Ltd. · Amano Enzyme Asia Pacific Co., Ltd. · Amano Commercial Fim Co., Ltd. (Affiliated)

Business model · enzymes

Amano Enzyme Inc. manufactures and sells enzyme agents for the pharmaceutical, food, and manufacturing industries, as well as diagnostic reagents, pharmaceuticals, veterinary medicines, and feed additives. The company serves a global customer base, with over 70% of its sales generated from overseas markets. It earns revenue by leveraging its expertise in biotechnology and traditional fermentation to provide high-quality, specialized enzyme products tailored to customer needs.


Overseas sales account for over 70% of the company's total sales.
“As the world continues to globalize, overseas sales make up over 70% of our sales, with this number growing each year.”
www.amano-enzyme.com weak (company, news, market research, other)

The company was founded in 1899 and began manufacturing enzymes in 1948.
“Founded in 1899, Amano Enzyme began manufacturing enzymes in 1948 and has since been supplying them to markets around the world for over 70 years.”
www.amano-enzyme.com weak (company, news, market research, other)

The company maintains an extensive strain library containing over 20,000 microorganisms.
“Amano has an extensive strain library (over 20,000 microorganisms obtained from a variety of environments such as deep sea) Innovation center and production technology center continue working on the discovery of new …”
www.amano-enzyme.com weak (company, news, market research, other)
Enzymes for Edoxaban intermediate synthesis
Enzymatic methods for producing Edoxaban intermediates replace traditional chemical synthesis, reducing organic solvents by 90%, raw material costs by 50%, and filtration times from 7 to 3.
“Edoxaban, an oral anticoagulant, is conventionally produced by chemical methods, but it has recently been reported that a portion of the intermediate synthesis can be replaced by enzymatic methods, thereby reducing …”
www.amano-enzyme.com weak (company, news, market research, other)
YL-T, Nuclease, and Deamizyme T
Amano's enzyme solutions for yeast extract production enable a one-step, one-vessel process that cuts production time by 27%.
“Amano Enzyme enables yeast extract manufacturers to create high-quality yeast extracts with increased yields of IMP and GMP while shortening production time by 27%.”
lp.amano-enzyme.com weak (company, news, market research, other)
Dextranase L Amano
Dextranase L Amano replaces the use of anti-biotic agents for controlling dextran during sugar processing and reduces energy consumption and waste.
“Through our experience in Japan, only Dextranase is used controlling MK value during the process (no anti-biotic agents at all).”
slideum.com weak (company, news, market research, other)
Thermostable microbial β-amylase
Thermostable microbial β-amylase replaces barley or wheat-derived enzymes in maltose syrup production, offering higher reaction temperatures and better suitability for starch liquefaction.
“The microbial enzyme was demonstrated to be superior to the barley- or wheat-derived enzymes, which are currently used in the production of maltose syrup.”
www.amano-enzyme.com weak (company, news, market research, other)

Status

    Recent news 5

    Found by automated search; summaries are machine-written in English. The headline names the company or the summary is about it — check the source before relying on it.

    Network: owners, partners, peers

    Ownership & investors 5

    subsidiaryAmano Enzyme U.S.A. Co., Ltd
    subsidiaryAmano Enzyme Europe Ltd
    subsidiaryAmano Enzyme Manufacturing
    subsidiaryAmano Enzyme Asia Pacific Co., Ltd
    subsidiaryAmano Commercial Fim Co., Ltd

    Similar companies

    SHANDONG LONCT ENZYMES CO.,LTD · S.I. Biozyme · Qingdao Vland Biotech Group Co., Ltd. · Mianyang Habio Bioengineering Co., Ltd · KDN Biotech (SHANGHAI) CO., LTD · Leveking Biotech · XIKE Enzymes · Vland Enzymes

    Company facts

    Registry identifiers

    • Corporate Number (Japan): 7180001034007

    From automated research (company websites, filings, a commercial company index); not checked by hand. Registry identifiers: confirm in the official registry.

    Identity & contacts

    Contacts, people and legal identity are available to members.

    Sign in as a member